Literature DB >> 17472887

Frame-based immobilization and targeting for stereotactic body radiation therapy.

Bryan Murray1, Kenneth Forster, Robert Timmerman.   

Abstract

Frame-based stereotactic body radiation therapy (SBRT), such as that conducted with Elekta's Stereotactic Body Frame, can provide an extra measure of precision in the delivery of radiation to extracranial targets, and facilitates secure patient immobilization. In this paper, we review the steps involved in optimal use of an extra-cranial immobilization device for SBRT treatments. Our approach to using frame-based SBRT consists of 4 steps: patient immobilization, tumor and organ motion control, treatment/planning correlation, and daily targeting with pretreatment quality assurance. Patient immobilization was achieved with the Vac-Loc bag, which uses styrofoam beads to conform to the patient's shape comfortably within the body frame. Organ and motion control was assessed under fluoroscopy and controlled via a frame-mounted abdominal pressure plate. The compression screw was tightened until the diaphragmatic excursion range was < 1 cm. Treatment planning was performed using the Philips Pinnacle 6.2b system. In this treatment process, a 20 to 30 noncoplanar beam arrangement was initially selected and an inverse beam weight optimization algorithm was applied. Those beams with low beam weights were removed, leaving a manageable number of beams for treatment delivery. After planning, daily targeting using computed tomography (CT) to verify x-, y-, and z-coordinates of the treatment isocenter were used as a measure of quality assurance. We found our daily setup variation typically averaged < 5 mm in all directions, which is comparable to other published studies on Stereotactic Body Frame. Treatment time ranged from 30 to 45 minutes. Results demonstrate that patients have experienced high rates of local control with acceptable rates of severe side effects - by virtue of the tightly constrained treatment fields. The body frame facilitated comfortable patient positioning and quality assurance checks of the tumor, in relation to another set of independent set of coordinates defined by the body frame fiducials. The ability to impose abdominal compression proved to be a simple way to reduce target and tissue motion. SBRT with Stereotactic Body Frame enables comfortable patient immobilization and facilitates repeated registering and re-registering of the patient to the frame. With the body frame, large-dose-per fraction treatment is possible for localized tumor deposits with the aim of attaining a more therapeutic result.

Entities:  

Mesh:

Year:  2007        PMID: 17472887     DOI: 10.1016/j.meddos.2007.01.005

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  10 in total

1.  Accuracy and reproducibility of tumor positioning during prolonged and multi-modality animal imaging studies.

Authors:  Mutian Zhang; Minming Huang; Carl Le; Pat B Zanzonico; Filip Claus; Katherine S Kolbert; Kyle Martin; C Clifton Ling; Jason A Koutcher; John L Humm
Journal:  Phys Med Biol       Date:  2008-09-30       Impact factor: 3.609

2.  Adapting liver motion models using a navigator channel technique.

Authors:  T N Nguyen; J L Moseley; L A Dawson; D A Jaffray; K K Brock
Journal:  Med Phys       Date:  2009-04       Impact factor: 4.071

3.  Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer.

Authors:  John H Heinzerling; Ross Bland; John C Mansour; Roderich E Schwarz; Ezequiel Ramirez; Chuxiong Ding; Ramzi Abdulrahman; Thomas P Boike; Timothy Solberg; Robert D Timmerman; Jeffrey J Meyer
Journal:  Radiat Oncol       Date:  2011-10-28       Impact factor: 3.481

Review 4.  Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.

Authors:  Percy Lee; Billy W Loo; Tithi Biswas; George X Ding; Issam M El Naqa; Andrew Jackson; Feng-Ming Kong; Tamara LaCouture; Moyed Miften; Timothy Solberg; Wolfgang A Tome; An Tai; Ellen Yorke; X Allen Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-04-05       Impact factor: 8.013

5.  A dosimetric comparison of stereotactic body radiation therapy techniques for lung cancer: robotic versus conventional linac-based systems.

Authors:  Chuxiong Ding; Cheng-Hui Chang; Joshua Haslam; Robert Timmerman; Timothy Solberg
Journal:  J Appl Clin Med Phys       Date:  2010-06-29       Impact factor: 2.102

6.  Development of a novel low-radiation-absorbent lok-bar to reduce X-ray scattering and absorption in RapidArc® treatment planning and dose delivery.

Authors:  Hajime Monzen; Kazuki Kubo; Mikoto Tamura; Masaru Hayakawa; Yasumasa Nishimura
Journal:  J Appl Clin Med Phys       Date:  2017-04-06       Impact factor: 2.102

7.  Deep inspiration breath-hold technique guided by an opto- electronic system for extracranial stereotactic treatments.

Authors:  Cristina Garibaldi; Gianpiero Catalano; Guido Baroni; Barbara Tagaste; Marco Riboldi; Maria Francesca Spadea; Mario Ciocca; Raffaella Cambria; Flavia Serafini; Roberto Orecchia
Journal:  J Appl Clin Med Phys       Date:  2013-07-08       Impact factor: 2.102

8.  Development and clinical evaluation of a simple optical method to detect and measure patient external motion.

Authors:  Benigno Barbés; Juan Diego Azcona; Elena Prieto; José Manuel de Foronda; Marina García; Javier Burguete
Journal:  J Appl Clin Med Phys       Date:  2015-09-08       Impact factor: 2.102

9.  Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer.

Authors:  Konstantina Karava; Stefanie Ehrbar; Oliver Riesterer; Johannes Roesch; Stefan Glatz; Stephan Klöck; Matthias Guckenberger; Stephanie Tanadini-Lang
Journal:  Radiat Oncol       Date:  2017-11-09       Impact factor: 3.481

10.  Study on Motion Management of Pancreatic Cancer Treated by CyberKnife.

Authors:  Shenghua Jing; Changchen Jiang; Xiaoqin Ji; Xiangnan Qiu; Jing Li; Xiangdong Sun; Xixu Zhu
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.